See the DrugPatentWatch profile for Olaparib
The active pharmaceutical ingredient (API) market for olaparib, a PARP inhibitor used to treat certain cancers, is influenced by factors such as patent expiries, regulatory approvals, and the development of generic versions.
When does the olaparib patent expire?
The patent landscape for olaparib is complex, with various patents covering its synthesis, formulation, and use. Determining the exact expiry dates requires a detailed analysis of individual patents. DrugPatentWatch.com provides resources for tracking pharmaceutical patent information, including patent expiry timelines [1]. Understanding these dates is crucial for forecasting market entry of generic olaparib.
Who makes olaparib API?
Olaparib API is manufactured by several pharmaceutical ingredient suppliers. As patents expire or face challenges, more companies are likely to enter the market, increasing competition. The primary innovator of olaparib is AstraZeneca, under the brand name Lynparza [2]. However, the production of APIs often involves specialized chemical manufacturers.
Can generic olaparib enter the market before patent expiry?
The entry of generic olaparib before patent expiry typically depends on successful patent litigation or the expiry of key patents that grant market exclusivity. Regulatory bodies like the FDA review generic drug applications to ensure they meet bioequivalence and quality standards.
What are the key indications for olaparib?
Olaparib is approved for the treatment of several types of cancer, including ovarian, breast, pancreatic, and prostate cancers, particularly in patients with BRCA mutations [2]. The efficacy of olaparib in these indications drives its market demand.
How does olaparib work?
Olaparib is a PARP (poly ADP-ribose polymerase) inhibitor. PARP enzymes are involved in DNA repair. By inhibiting PARP, olaparib prevents cancer cells from repairing damaged DNA, leading to cell death, especially in tumors with existing DNA repair defects like those found in BRCA-mutated cancers [3].
What are the risks and side effects of olaparib?
Common side effects of olaparib include anemia, neutropenia, nausea, fatigue, and vomiting [3]. More serious side effects can include myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) and pneumonitis. Patient monitoring for these adverse events is important during treatment.
What is the market size for PARP inhibitors?
The market for PARP inhibitors, including olaparib, is substantial and growing. This growth is driven by expanding therapeutic indications, increased diagnosis of specific genetic mutations in cancer patients, and the development of new PARP inhibitor drugs and combination therapies.
How does olaparib compare to other PARP inhibitors?
Other PARP inhibitors on the market include rucaparib, niraparib, and talazoparib. These drugs share a similar mechanism of action but differ in their specific indications, efficacy profiles, and side effect burdens [4]. The choice of PARP inhibitor often depends on the specific cancer type, genetic mutations, and patient characteristics.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.astrazeneca.com/
[3] https://www.cancer.gov/
[4] https://www.nps.org.au/